PHAT 16.00 Phathom Pharmaceuticals, Inc.
| Range: | 6.065-19.71 | Vol Avg: | 958215 | Last Div: | 0 | Changes: | -0.62 |
| Beta: | 0.71 | Cap: | 1.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 25 2019 | Empoloyees: | 452 | ||
| CUSIP: | 71722W107 | CIK: | 0001783183 | ISIN: | US71722W1071 | Country: | US |
| CEO: | Ms. Terrie J. Curran | Website: | https://www.phathompharma.com | ||||
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Stock Details
PHAT 12
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
Paul Choi·Thu Aug 08 2024
Goldman Sachs
PHAT 28
H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
Matthew Caufield·Fri Jul 19 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow